Digital Pathology and Personalized Medicine News and Discussion

Latest Headlines

Webinar Postponed: Aperio and Definiens Present the Full Spectrum of Applications for Quantitative ePathology

Posted on Monday, May 14, 2012

Learn how Aperio ePathology and Definiens can be utilized for quantitative assessment of tissues in preclinical safety studies. Solutions for measuring stain intensity, quantifying morphological features of cell and cellular structures, describing spatial relationships, and mining and reporting data will be presented.

The webinar was rescheduled: Wednesday, June 20, 2012 – 7am PDT / 10am EDT / 5pm CEST

Click here to register.

Definiens Expands Functionality of Its Leading Solution for Quantitative Digital Pathology with Gene Probe Analysis

Posted on Thursday, May 10, 2012

Definiens Tissue Studio Now Supports the Detection of Spot-like Signals from In Situ Hybridization Assays

Munich, Germany, May 10, 2012Definiens®, the leading provider of image analysis and data mining solutions for quantitative digital pathology, today announced that Definiens Tissue Studio® 3.5 now supports the automated analysis of in situ hybridization assays, including SISH, CISH, FISH and dual-ISH. The unique combination of flexibility and ease-of-use that characterizes Definiens Tissue Studio® significantly facilitates the detection of spot-like signals originating from gene probes (or any other stain with spot-like appearance) on a cell-by-cell basis. Definiens Tissue Studio® supports the detection of gene probe signals in both brightfield and immunofluorescene imaging. Read More…

DPA Webinar Series: “Barriers to the Adoption of Digital Pathology”

Posted on Tuesday, May 8, 2012

The Digital Pathology Association (DPA) in partnership with the Association of Pathology Informatics and CAP Today will host a series of four, one-hour webinars in 2012 focusing on the barriers to adoption of digital pathology. The topics to be addressed during the webinars include: a cultural and strategic perspective, regulatory issues, financial aspects of deployment, and technical considerations. Read More…